Financial Performance - The company's operating revenue for Q3 2025 was ¥162,282,968.92, representing a year-on-year increase of 10.37%[4] - The total profit for the period was -¥32,443,751.20, a decrease of 199.90% compared to the same period last year[4] - The net profit attributable to shareholders was -¥15,327,234.69, down 148.44% year-on-year[4] - The basic earnings per share for the period was -¥0.12, a decrease of 150.00% year-on-year[4] - The diluted earnings per share for the period was also -¥0.12, reflecting a 150.00% decline compared to the same period last year[4] - Total operating revenue for the first three quarters of 2025 was CNY 422,626,267.10, a decrease of 15.6% compared to CNY 500,553,520.06 in the same period of 2024[20] - The company reported a net loss of CNY 55,905,406.41 for the first three quarters of 2025, compared to a net profit of CNY 36,958,353.67 in the same period of 2024[22] - Operating profit for the first three quarters of 2025 was CNY -84,182,421.89, a significant decline from CNY 30,568,123.68 in 2024[21] - Basic and diluted earnings per share for the first three quarters of 2025 were both CNY -0.42, compared to CNY 0.28 in the same period of 2024[22] - The total comprehensive income for the first three quarters of 2025 was CNY -67,951,341.30, compared to CNY 35,563,906.33 in 2024, indicating a negative shift[33] Research and Development - Research and development expenses totaled ¥39,796,629.50, an increase of 54.42% compared to the same period last year, accounting for 24.52% of operating revenue[5] - The company reported a significant increase in R&D investment as part of its long-term strategic initiatives, which has temporarily raised expense ratios[9] - Research and development expenses remained stable at CNY 113,605,753.86, compared to CNY 113,108,128.27 in the previous year[21] - The company's research and development expenses for the first three quarters of 2025 were CNY 115,029,853.81, slightly down from CNY 117,707,540.36 in 2024, reflecting a focus on maintaining R&D investment[32] Assets and Liabilities - The total assets at the end of the period were ¥1,826,626,179.89, reflecting a 4.46% increase from the end of the previous year[5] - Total current assets as of September 30, 2025, amount to ¥957,088,840.04, a decrease from ¥992,858,871.93 as of December 31, 2024[15] - The company's total equity decreased to CNY 1,207,126,914.47 from CNY 1,345,530,786.40 year-over-year[30] - Total liabilities rose to CNY 566,516,917.74, compared to CNY 368,197,409.69, reflecting an increase of 53.8%[17] - Total assets increased to CNY 1,826,626,179.89, up from CNY 1,748,676,638.82, indicating growth in the company's asset base[17] - The company's equity attributable to shareholders decreased to CNY 1,245,498,643.09 from CNY 1,366,055,677.44, a decline of 8.8%[17] Shareholder Information - Total number of common shareholders at the end of the reporting period is 5,549[12] - The largest shareholder, Gu Xiaozhou, holds 21,740,500 shares, representing 16.14% of total shares[13] - The second largest shareholder, Gu Kang, holds 16,950,200 shares, representing 12.59% of total shares[13] - The company has no significant changes in the top 10 shareholders due to margin trading activities[13] Cash Flow - Cash inflow from operating activities for the first three quarters of 2025 was CNY 544,196,815.48, a slight increase from CNY 528,105,962.51 in the same period of 2024[25] - Net cash outflow from operating activities was CNY -98,694,502.97, improving from CNY -137,907,116.60 year-over-year[25] - Cash inflow from investment activities increased significantly to CNY 744,302,144.95 in 2025, compared to CNY 339,633,242.06 in 2024[26] - Net cash flow from investment activities was CNY 17,160,147.57, a turnaround from CNY -11,990,148.86 in the previous year[26] - Cash inflow from financing activities rose to CNY 442,017,678.34, up from CNY 110,525,317.50 in 2024[26] - Net cash flow from financing activities was CNY 148,073,526.96, compared to CNY 50,113,987.87 in the same period last year[26] Other Financial Metrics - The company's cash and cash equivalents at the end of the period were CNY 317,327,628.17, up from CNY 144,940,689.86 in the previous year[26] - The company's financial expenses in 2025 included interest expenses of CNY 4,447,934.20, compared to CNY 773,484.38 in 2024, indicating an increase in borrowing costs[32] - Deferred tax assets increased significantly to CNY 75,214,162.80 from CNY 44,840,115.68, indicating a potential future tax benefit[17]

证券代码：688212 证券简称：澳华内镜 公告编号：2025-065 上海澳华内镜股份有限公司 关于调整经营范围并修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海澳华内镜股份有限公司（以下简称"公司"）于2025年10月27日召开 第二届董事会第二十一次会议，审议通过了《关于调整经营范围并修订<公司章 程>的议案》，本事项尚需提交公司股东大会审议。现将相关事项公告如下： 一、调整公司经营范围的情况 根据公司实际情况及经营发展需要，公司拟对经营范围进行调整，调整前 后对比如下： | 序号 | 调整前 | 调整后 | | --- | --- | --- | | | 公司的经营范围：许可项目：第二类医 | 公司的经营范围：许可项目：第二类医疗 | | | 疗器械生产；第三类医疗器械生产；第 | 器械生产；第三类医疗器械生产；第三类 | | | 三类医疗器械经营。（依法须经批准的 | 医疗器械经营。（依法须经批准的项目， | | | 项目，经相关部门批准后方可开展经营 | 经相关部门批准后方可开展经营 ...

Group 1 - The core viewpoint of the news is that Aohua Endoscopy has seen a stock price increase of 5.1%, reaching 51.73 yuan per share, with a total market capitalization of 6.966 billion yuan [1] - Aohua Endoscopy, established on October 27, 1994, specializes in the research, production, and sales of electronic endoscope equipment and related medical consumables, with 92.35% of its revenue coming from endoscope equipment [1] - The company is classified as a high-tech enterprise, with additional revenue sources including endoscope consumables (3.71%), maintenance services (3.58%), and leasing (0.35%) [1] Group 2 - Xiangcai Fund has a significant holding in Aohua Endoscopy, with its Xiangcai Medical Health Mixed A fund holding 18,000 shares, representing 4.8% of the fund's net value [2] - The fund has achieved a year-to-date return of 44.3%, ranking 1642 out of 8155 in its category, and a one-year return of 36.51%, ranking 2016 out of 8029 [2] - The fund manager, Zhang Quan, has been in position for 1 year and 308 days, with the fund's total assets amounting to 18.3775 million yuan [3]

Core Insights - The medical device sector experienced a slight increase of 0.37% on October 24, with Mai Lande leading the gains [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Medical Device Sector Performance - Top gainers included: - Mai Lande (688273) with a closing price of 41.92, up 6.31%, trading volume of 29,300 hands, and a transaction value of 121 million yuan [1] - Xiangyu Medical (688626) at 53.21, up 6.10%, with a trading volume of 41,100 hands and a transaction value of 216 million yuan [1] - Xiangsheng Medical (688358) at 35.27, up 4.75%, with a trading volume of 38,400 hands and a transaction value of 136 million yuan [1] - Other notable gainers included: - Aohua Endoscopy (688212) at 50.59, up 4.74%, with a transaction value of 225 million yuan [1] - Weisi Medical (688580) at 49.10, up 4.71%, with a transaction value of approximately 99.8 million yuan [1] Decliners in Medical Device Sector - Notable decliners included: - Chenguang Medical (920300) at 17.51, down 8.80%, with a trading volume of 124,000 hands [2] - Toukeng Life (300642) at 22.95, down 5.40%, with a trading volume of 175,700 hands [2] - Haitai New Light (688677) at 48.50, down 5.05%, with a trading volume of 38,800 hands [2] - Other significant decliners included: - Sino Medical (688108) at 28.00, down 4.73%, with a trading volume of 263,700 hands [2] - Tianchen Medical (688013) at 55.66, down 3.98%, with a trading volume of 19,200 hands [2] Capital Flow in Medical Device Sector - The medical device sector saw a net outflow of 654 million yuan from major funds, while retail investors contributed a net inflow of 455 million yuan [2]

Core Points - The Shanghai Composite Index closed at 3938.98 points, above the six-month moving average, with a gain of 0.42% [1] - A total trading volume of A-shares reached 1,239.319 billion yuan today [1] - 126 A-shares have surpassed the six-month moving average, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - The top three stocks with the highest deviation rates from the six-month moving average are: - Xicet Testing (西测测试) with a deviation rate of 13.84% and a daily increase of 15.21% [2] - Anhui Instrument Technology (皖仪科技) with a deviation rate of 9.60% and a daily increase of 12.74% [2] - Aerospace Changfeng (航天长峰) with a deviation rate of 9.37% and a daily increase of 10.01% [2] Trading Metrics - The trading turnover rate for Xicet Testing was 18.16%, while Anhui Instrument Technology had a turnover rate of 3.91% [2] - The latest prices for the top three stocks are: - Xicet Testing at 58.87 yuan [2] - Anhui Instrument Technology at 24.33 yuan [2] - Aerospace Changfeng at 15.17 yuan [2] Additional Stocks - Other notable stocks with significant performance include: - Tongfeng Electronics (铜峰电子) with a deviation rate of 9.10% and a daily increase of 9.95% [2] - Weihong Technology (维宏股份) with a deviation rate of 7.25% and a daily increase of 10.74% [2] - China Satellite Communications (中国卫通) with a deviation rate of 5.82% and a daily increase of 6.02% [2]

Group 1 - The core viewpoint of the news is that Aohua Endoscopy has seen a stock price increase of 5.3%, reaching 50.86 CNY per share, with a total market capitalization of 6.849 billion CNY [1] - Aohua Endoscopy, established on October 27, 1994, specializes in the research, production, and sales of electronic endoscope equipment and related medical consumables, with 92.35% of its revenue coming from endoscope equipment [1] - The company is located in Minhang District, Shanghai, and was listed on November 15, 2021 [1] Group 2 - Among the top ten circulating shareholders of Aohua Endoscopy, one fund from GF Fund Management, the GF Healthcare Stock A (004851), has entered the list, holding 1.7267 million shares, which is 1.28% of the circulating shares [2] - The GF Healthcare Stock A fund was established on August 10, 2017, and has a current scale of 5.247 billion CNY, with a year-to-date return of 19.8% [2] - The fund's performance ranks 2665 out of 4218 in its category this year, and it has achieved a cumulative return of 93.64% since inception [2] Group 3 - The fund manager of GF Healthcare Stock A is Wu Xingwu, who has been in the position for 10 years and 258 days, managing assets totaling 9.853 billion CNY [3] - During his tenure, the best fund return achieved was 105.25%, while the worst return was -37.23% [3]

Group 1 - The core viewpoint of the news is that Aohua Endoscopy has seen a significant increase in its stock price, rising by 5.45% to 49.88 CNY per share, with a total market capitalization of 6.717 billion CNY [1] - Aohua Endoscopy, established on October 27, 1994, is a high-tech enterprise located in Shanghai, primarily engaged in the research, production, and sales of electronic endoscopy equipment and related medical consumables [1] - The company's main revenue sources are: endoscopy equipment (92.35%), endoscopy consumables (3.71%), endoscopy maintenance services (3.58%), and leasing income (0.35%) [1] Group 2 - Aohua Endoscopy is a significant holding in the fund managed by Agricultural Bank of China, with the Aohua Endoscopy stock representing 2.58% of the fund's net value, making it the fifth-largest holding [2] - The Agricultural Bank of China fund, named Agricultural Bank of China Specialized and New Mixed A (016305), has achieved a year-to-date return of 39.95% and ranks 1392 out of 8162 in its category [2] - The fund manager, Wei Gang, has been in charge for over 7 years, with the best fund return during his tenure being 121.47% [3]

Group 1 - The core viewpoint of the news is that Aohua Endoscopy experienced a stock price increase of 5.45%, reaching 49.88 CNY per share, with a total market capitalization of 6.717 billion CNY [1] - Aohua Endoscopy, established on October 27, 1994, is a high-tech enterprise located in Shanghai, primarily engaged in the research, production, and sales of electronic endoscopy equipment and related medical consumables [1] - The revenue composition of Aohua Endoscopy includes 92.35% from endoscopy equipment, 3.71% from endoscopic diagnostic consumables, 3.58% from maintenance services, and 0.35% from leasing [1] Group 2 - Among the top ten circulating shareholders of Aohua Endoscopy, ICBC Credit Suisse Fund's Aohua Medical Stock A (001717) reduced its holdings by 805,800 shares, now holding 3.0942 million shares, which is 2.3% of the circulating shares [2] - The Aohua Medical Stock A fund has achieved a year-to-date return of 26.76% and a one-year return of 20.01%, ranking 1686 out of 4218 and 2253 out of 3868 in its category, respectively [2] - The fund manager, Zhao Bei, has been in position for 10 years and 341 days, with the fund's total asset size at 16.425 billion CNY and a best return of 233% during his tenure [3]

Core Insights - As of October 17, a total of 84 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more [1] - The stocks with the longest streak of net buying are Kaisheng Technology and Jianyou Co., both of which have seen net buying for 10 consecutive trading days [1] - Other notable stocks with significant net buying days include Wuxi Zhenhua, Jintou Chengkai, Zhucheng Technology, Lianyu Co., Yongmaotai, Yan'ao Co., Aohua Endoscopy, and Kesi Technology [1]

Group 1 - The stock price of Aohua Endoscopy has declined by 1.57% to 46.25 CNY per share, with a total market capitalization of 6.228 billion CNY, and a cumulative drop of 9.46% over the last four days [1] - Aohua Endoscopy, established on October 27, 1994, specializes in the research, production, and sales of electronic endoscope equipment and related medical consumables, with 92.35% of its revenue coming from endoscope equipment [1] Group 2 - Beixin Ruifeng Fund holds 100,000 shares of Aohua Endoscopy in its health lifestyle theme flexible allocation fund, representing 5.48% of the fund's net value, with a floating loss of approximately 74,000 CNY today and 483,000 CNY over the four-day decline [2] - The Beixin Ruifeng Health Lifestyle Theme Flexible Allocation Fund (001056) has a total scale of 90.1431 million CNY and has achieved a year-to-date return of 29.83% [2]